During the past decade, it has become evident that in vitro enzyme data obtained in solution frequently fail to provide an accurate profile of in vivo enzyme kinetic parameters. This may be due to oligomer formation. Efforts to separate the effect of oligomer formation on P450 kinetics from factors that might influence kinetic parameters have been incomplete and are necessary to quantify the contribution that oligomer formation has on P450-mediated metabolism kinetics, to improve estimations of in vivo drug clearance. Our long-term goal is to accurately predict in vivo drug pharmacokinetics from in vitro data to improved assessments of drug safety and efficacy. Our overall objective here is to determine the important factors influencing in vitro P450-mediated metabolism kinetics through studies of homo- and hetero-oligomer formation using our recently developed immobilized enzyme methods. Our central hypothesis is that CYP2C9-mediated metabolism kinetics measured in vitro are critically dependent on the state of oligomerization, and to accurately predict in vivo pharmacokinetics using in vitro data requires inclusion of this variable. Our rationale for this project is that successful completion would provide a solid scientific foundation to more accurately assess in vivo kinetics of metabolism based upon in vitro data. To achieve our overall objectives, we propose to quantitate the modulatory effects of CYP2C9 homo and hetero-oligomer formation on enzyme kinetics. Successful achievement of this goal will well position us to determine the key factors that explain altered enzyme kinetics of oligomers versus monomers. The proposed research is innovative as a novel immobilized P450 methodology will be employed to unequivocally evaluate the effect of oligomerization on the kinetics of metabolism. Our expected outcomes are 1) determination of selected physical-chemical factors that affect CYP2C9 kinetics using nanoscale methods for protein manipulation and 2) to have quantitated the extent to which oligomer formation modulates CYP2C9-mediated metabolism kinetics. These outcomes are significant as they will help to further delineate the mechanistic details of P450 metabolism, an enzyme system responsible for metabolism of the majority of drugs, and should lead to improved pharmacokinetic data, necessary for determination of correct dosages and thus ultimately improve patient care.

Public Health Relevance

Data from in vitro experiments are routinely used during the drug development process to predict the disposition of a drug in humans to better determine initial doses. However, it has now become apparent that interactions between the drug metabolism proteins may alter the these results and affect the ability to correctly predict human doses. Better understanding of these protein-protein interactions will lead to more accurate predictions of drug disposition and thus, improved patient safety and drug efficacy.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM086891-01
Application #
7591556
Study Section
Special Emphasis Panel (ZRG1-DIG-F (02))
Program Officer
Okita, Richard T
Project Start
2009-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$367,463
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Bostick, Chris D; Hickey, Katherine M; Wollenberg, Lance A et al. (2016) Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism. Drug Metab Dispos 44:741-9
Bostick, Christopher D; Flora, Darcy R; Gannett, Peter M et al. (2015) Nanoscale electron transport measurements of immobilized cytochrome P450 proteins. Nanotechnology 26:155102
Wollenberg, Lance A; Kabulski, Jarod L; Powell, Matthew J et al. (2014) The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites. Appl Biochem Biotechnol 172:1293-306
Ramsden, Diane; Tweedie, Donald J; Chan, Tom S et al. (2014) Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions. Drug Metab Dispos 42:1940-6
Jett, John E; Lederman, David; Wollenberg, Lance A et al. (2013) Measurement of electron transfer through cytochrome P450 protein on nanopillars and the effect of bound substrates. J Am Chem Soc 135:3834-40
Li, Debin; Gannett, Peter M; Lederman, David (2012) An investigation into the feasibility of myoglobin-based single-electron transistors. Nanotechnology 23:395705
Wollenberg, Lance A; Jett, John E; Wu, Yueting et al. (2012) Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes. Nanotechnology 23:385101
Subramanian, Murali; Tam, Harrison; Zheng, Helen et al. (2010) CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos 38:1003-9